Stevanato Group (STVN) Q3 Earnings Match Estimates

Core Viewpoint - Stevanato Group reported quarterly earnings of $0.13 per share, matching the Zacks Consensus Estimate, but down from $0.16 per share a year ago [1] - The company generated revenues of $305.42 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 1.89% and up from $295.39 million year-over-year [2] Financial Performance - Over the last four quarters, Stevanato has not surpassed consensus EPS estimates [2] - The company has topped consensus revenue estimates two times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.19 on revenues of $355.64 million, and for the current fiscal year, it is $0.50 on revenues of $1.2 billion [7] Stock Performance - Stevanato shares have declined approximately 29% since the beginning of the year, contrasting with the S&P 500's gain of 19.8% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Outlook - The Medical - Drugs industry, to which Stevanato belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]